Drug intelligence / Profile preview

MUC1 antibody-functionalized microparticles

Development stage
Preclinical
Modality
Nanoparticles → Drug Delivery Systems, Antibody-Based Therapeutics
Administration
Topical
01

Overview

MUC1 antibody-functionalized microparticles are an experimental diagnostic and targeted delivery system designed to detect and visualize colorectal cancer (CRC) lesions. These microparticles utilize a "universal" surface functionalization approach, often employing a Protein L scaffold (APL-MPs) to incorporate antibodies specific to Mucin-1 (MUC1). MUC1 is a heavily glycosylated transmembrane protein that is significantly overexpressed on the surface of various epithelial cancers, including colorectal, breast, and pancreatic cancers. By binding specifically to MUC1 antigens on the luminal surface of the colon, these microparticles facilitate the detection of heterogeneous tumor lesions that might be missed by conventional visualization techniques. Preclinical evaluations in 3D tumoroids and orthotopic animal models have demonstrated that these particles can identify MUC1-positive tissues in proportion to antigen expression, serving as a modular platform for precision imaging of diverse tumor phenotypes.

Other names
Mucin-1 targeting microparticlesMucin1 targeting microparticlesMucin 1 targeting microparticlesMUC1-targeting APL-MPsMUC-1-targeting APL-MPsMUC 1-targeting APL-MPsAntibody-Protein L functionalized microparticles
02

Targets

MUC1 (Mucin-1 Antigen)

Beyond the preview

Go deeper on MUC1 antibody-functionalized microparticles.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MUC1 antibody-functionalized microparticles.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call